BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lyrfigtu (lirafugratinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lyrfigtu (lirafugratinib)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07359820-10824@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lyrfigtu (lirafugratinib): Phase 2 readout est. (NCT07359820)
DESCRIPTION:Lyrfigtu (lirafugratinib)\, phase 2.\nStudy: A Study of Lirafug
 ratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lirafugratinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07359820
URL:https://assetmemo.bio/drug/lirafugratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
